Hexapan-D Capsule PR is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide symptomatic relief in gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility by enhancing gastric emptying and reducing nausea and vomiting. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby promoting ulcer healing and symptom relief in acid-related conditions. Hexapan-D Capsule PR is indicated for the management of gastroesophageal reflux disease (GERD), dyspepsia, gastritis, and other acid-peptic disorders where delayed gastric emptying and acid hypersecretion coexist. The combination therapy offers a dual mechanism of action, improving gastric motility while effectively controlling acid secretion, which enhances patient compliance and therapeutic outcomes. The prolonged-release formulation ensures sustained drug levels, optimizing efficacy and minimizing dosing frequency. Hexapan-D Capsule PR should be used under medical supervision, with caution advised in patients with known hypersensitivity to either component, underlying cardiac conditions, or hepatic impairment. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. It is contraindicated in patients with prolactinoma or gastrointestinal obstruction.